Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 1
Testing an oncolytic virus injected into tumors in pancreatic cancer
Tests ORCA-010, a virus injected into tumors, in adults with metastatic pancreatic cancer.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- PANVIRAL: Safety, Feasibility and Immunogenicity of Intra-Tumoral ORCA-010 Oncolytic Virus Administration in Metastatic Pancreatic Cancer – A Single-Center Phase 1 Trial
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 1 Jan 2029
- Type of study
- Interventional
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic pancreatic cancer to test the safety and immune response of ORCA-010, an oncolytic virus injected into the tumor.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Metastatic pancreatic cancer
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Testing an oncolytic virus injected into tumors in pancreatic cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 9 October 2026